Please login to the form below

Not currently logged in
Email:
Password:

guselkumab

This page shows the latest guselkumab news and features for those working in and with pharma, biotech and healthcare.

NICE’s fast-track catapults Skyrizi into market

NICE’s fast-track catapults Skyrizi into market

ustekinumab). It added that indirect comparisons suggest Skyrizi is likely to provide similar health benefits compared with Tremfya (guselkumab) and better PASI (Psoriasis Area and Severity Index) response rates compared with

Latest news

More from news
Approximately 2 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics